On October 17, 2022 Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has reported a collaborative development and reseller agreement with GE Healthcare to supply its investigational positron emission tomography (PET) imaging radiotracers, TLX250-CDx (89Zr-DFO-girentuximab), and [18F]-FLac (18F-3-fluoro-2-hydroxypropionate) for use in third party clinical research and development activities (Press release, Telix Pharmaceuticals, OCT 17, 2022, View Source [SID1234622089]). These novel tracers offer the potential to provide key information about the metabolic environment of tumours, which could help to inform and improve therapy selection. The agreement was announced during the European Association of Nuclear Medicine (EANM) Congress in Barcelona, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TLX250-CDx – the subject of Telix’s recently completed Phase III ZIRCON study in clear cell renal cell carcinoma1 – targets the antigen, carbonic anhydrase IX (CAIX). Expressed in many solid tumour types, CAIX can be used to identify hypoxic tumours,2 cells that have been deprived of oxygen, which can correlate with disease progression and resistance to therapy, including immunotherapy. Identifying such tumours may guide changes in care, from immune checkpoint inhibitor (ICI) monotherapy to combination treatments that overcome the hypoxic barrier.
[18F]-FLac, which Telix in-licensed in 2021,3 has shown promise in imaging lactate metabolism in oxygenated tumours. High lactate in tumours could prevent ICI responses and additionally be harmful in patients receiving ICI therapies.4 Understanding tumour lactate metabolic status could guide treatment decisions towards immunotherapy combinations that overcome this barrier.
TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics’ pipeline of investigational non-invasive [18F]-CD8 and [18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy. Currently an average of only 20-40 percent of patients respond to immunotherapies, and patient suitability is typically determined by taking tumour biopsies.5
Jonathan Barlow, SVP Global Business Development & Alliance Management, Telix, said, "This partnership will see our investigational imaging agents used more widely in third-party clinical trials. Excitingly, it will also help to expedite the development of [18F]-FLac, while expanding the utility of our TLX250-CDx imaging candidate."
Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare’s Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics. These aim to enrich clinical trials for pharmaceutical companies with the possibility of determining the metabolic environment and immune status of tumours, and if successful, help to improve speed to market for potential therapies. Ultimately, these PET imaging diagnostics could assist in delivering effective oncology therapies to patients."
Under the agreement, GE Healthcare will be responsible for the directed marketing and sales of Telix’s imaging agents to pharmaceutical companies, with the close support of Telix, whilst Telix will be responsible for manufacturing and ongoing development of each product. Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare’s FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
The agreement has an initial term of five years, subject to review and termination rights based on performance after three years.